October 2026

Medical team performing a catheter procedure in Tashkent.
Clinical evaluation of the RoseDoc system in Tashkent, Uzbekistan, October 2026.

In October 2026, Prof. Horst Sievert worked with Prof. Amir Halkin, Dr. Alisher Yuldashov and the TruLeaf Medical team in Tashkent, Uzbekistan, on first-stage implantations of the RoseDoc system in two patients with severe tricuspid regurgitation.

RoseDoc separates anchoring from valve implantation. In these two patients, the docking systems were implanted percutaneously. Implantation of the prosthetic valves is planned as a second procedure in the coming months. The procedures in Tashkent therefore represent the first stage of treatment, rather than completed valve replacements.

The platform is being developed for patients with severe tricuspid regurgitation and is not limited to those who have undergone a previous repair. A particularly interesting potential application is treatment after failed transcatheter edge-to-edge repair (T-TEER), when existing repair devices can complicate further intervention. The docking concept may provide an additional option in this setting. Its role will need to be defined through further clinical evaluation.

These are early clinical cases. Completing the staged treatment and assessing follow-up outcomes will be essential to understanding the benefits and limitations of the approach. The interval between procedures and the practical implications of two separate interventions are also important parts of that assessment.

The development of RoseDoc brings together clinical and engineering expertise, including cardiac surgeon Prof. Oz Shapira, Chairman of TruLeaf Medical, and engineer Benjamin Spenser, the company’s co-founder and CEO. The work in Tashkent reflects collaboration between the visiting specialists, local colleagues and the TruLeaf team.

International clinical research and collaboration are central to Prof. Sievert’s work and to CardioVascular Global’s activities in the evaluation and development of cardiovascular technologies.

For further details, see Prof. Oz Shapira’s original LinkedIn post.

Clinical research and collaboration

Contact Us
Text Us

Accessibility Tools

Increase TextIncrease Text
Decrease TextDecrease Text
GrayscaleGrayscale
Invert Colors
Readable FontReadable Font
Reset